LIAISON® SARS-CoV-2 S1/S2 IgG

GUDID 08056771103664

DIASORIN SPA

SARS-CoV-2 immunoglobulin G (IgG) antibody IVD, kit, chemiluminescent immunoassay

• Primary Device ID: 08056771103664
• NIH Device Record Key: 3b9c48f0-481d-4493-96c7-e5c069f52f43
• Commercial Distribution Status: In Commercial Distribution
• Brand Name: LIAISON® SARS-CoV-2 S1/S2 IgG
• Version Model Number: 311460
• Company DUNS: 630822989
• Company Name: DIASORIN SPA
• Device Count: 1
• DM Exempt: false
• Pre-market Exempt: false
• MRI Safety Status: Labeling does not contain MRI Safety Information
• Human Cell/Tissue Product: false
• Device Kit: true
• Device Combination Product: false
• Single Use: false
• Lot Batch: true
• Serial Number: false
• Manufacturing Date: false
• Expiration Date: true
• Donation Id Number: false
• Contains Natural Rubber Latex: false
• Labeled No Natural Rubber Latex: false
• RX Perscription: true
• OTC Over-The-Counter: false

Customer Support Contacts

• Phone: 651-439-9710
• Email: info@diasorin.com

Device Identifiers

Device Issuing Agency	Device ID
GS1	08056771103664 [Primary]

FDA Product Code

• QKO: Reagent, Coronavirus Serological

Sterilization

• Steralize Prior To Use: false
• Device Is Sterile: false

Device Entry Metadata

• Public Version Status: New
• Device Record Status: Published
• Public Version Number: 1
• Public Version Date: 2020-05-05
• Device Publish Date: 2020-04-27

Devices Manufactured by DIASORIN SPA

• 08056771104029 - LIAISON® Biotrin Parvovirus B19 IgG Plus: 2024-04-16 Italy manufactured kit.
• 08056771104036 - LIAISON® Biotrin Control Parvovirus B19 IgG Plus: 2024-04-16 Italy manufactured kit.
• 08056771104166 - LIAISON® VZV IgG HT: 2024-03-25
• 08056771104173 - LIAISON® Control VZV IgG HT: 2024-03-25
• 08056771104098 - LIAISON QUANTIferon TB Gold Plus: 2023-12-22 Italy manufactured kit.
• 08056771104081 - LIAISON QUANTIferon TB Gold Plus: 2023-09-18 Italy manufactured kit.
• 08056771603300 - LIAISON QUANTIferon TB Gold Plus: 2023-07-31
• 08056771200103 - LIAISON® ENDOCRINOLOGY DILUENT: 2023-06-02